The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

The FDA has approved popular antiobesity drug Ozempic to help protect patients with type 2 diabetes from kidney disease.

The US Food and Drug Administration (FDA) approval is based on the clinical trials that showed how Ozempic, the diabetes drug ...

Ozempic, the GLP-1 drug initially approved by the U.S. Food and Drug Administration in 2017 to treat Type 2 diabetes, was recently OK’d to help reduce risks linked to chronic kidney disease (CKD).

The US Food and Drug Administration (FDA) has approved Novo Nordisk’s diabetes-cum-weight loss drug Ozempic for patients with both chronic kidney disease (CKD) and diabetes after clinical trials ...

The US Food and Drug Administration (FDA) has approved Novo Nordisk’s diabetes-cum-weight loss drug Ozempic for patients with both chronic kidney disease and diabetes. This came after clinical trials ...